Emerging Role of Fibroblast Growth Factors 15/19 and 21 as Metabolic Integrators in the Liver

被引：98

作者：

Cicione, Claudia ^{[1
]}

Degirolamo, Chiara ^{[1
]}

Moschetta, Antonio ^{[1
,2
,3
]}

机构：

[1] Consorzio Mario Negri Sud, Dept Translat Pharmacol, Lab Lipid Metab & Canc, Santa Maria Imbaro, CH, Italy

[2] Univ Bari, Clin Med A Murri, Dept Internal & Publ Med, I-66030 Chieti, Italy

[3] Natl Canc Inst Giovanni Paolo II, Bari, Italy

来源：

HEPATOLOGY | 2012年 / 56卷 / 06期

关键词：

ACTIVATED-RECEPTOR-GAMMA; BILE-ACID SYNTHESIS; BETA-KLOTHO; PPAR-ALPHA; HEPATOCELLULAR-CARCINOMA; CIRCADIAN-RHYTHM; TRANSGENIC MICE; MOUSE MODEL; EXPRESSION; FGF21;

D O I：

10.1002/hep.25929

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Fibroblast growth factors (FGFs) 15/19 and 21 belong to the FGF endocrine subfamily. They present the intriguing characteristic to be transcribed and secreted in certain tissues and to act as hormones. The insulin-mimetic properties of FGF21 and the regulatory role of FGF15/19 in bile acid and glucose homeostasis endorse these hormones as druggable targets in metabolic disorders. Here, we present details on discoveries, identification, transcriptional regulation, and mechanism of actions of FGF15/19 and FGF21 with a critical perspective view on their putative role as metabolic integrators in the liver. (HEPATOLOGY 2012;56:2404-2411)

引用

页码：2404 / 2411

页数：8

共 50 条

[31] Fibroblast growth factor 21 in metabolic syndrome
Yang, Ming
Liu, Chongbin
Jiang, Na
Liu, Yan
Luo, Shilu
Li, Chenrui
Zhao, Hao
Han, Yachun
Chen, Wei
Li, Li
Xiao, Li
Sun, Lin
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[32] Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease
Rysz, Jacek
Gluba-Brzozka, Anna
Mikhailidis, Dimitri P.
Banach, Maciej
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (05) : 603 - 610
[33] Optimization of Peptide Inhibitors of ß-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21
Pan, Jia
Parlee, Sebastian D.
Brunel, Florence M.
Li, Pengyun
Lu, Wei
Perez-Tilve, Diego
Liu, Fa
Finan, Brian
Kharitonenkov, Alexei
DiMarchi, Richard D.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (05) : 978 - 986
[34] Prometheus' little helper, a novel role for fibroblast growth factor 15 in compensatory liver growth
Schaap, Frank G.
Leclercq, Isabelle A.
Jansen, Peter L. M.
Damink, Steven W. Olde
JOURNAL OF HEPATOLOGY, 2013, 59 (05) : 1121 - 1123
[35] Fibroblast Growth Factor 21 (FGF-21) and Its Relation to Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver in Children: A Longitudinal Analysis
Reinehr, Thomas
Woelfle, Joachim
Wunsch, Rainer
Roth, Christian L.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (06) : 2143 - 2150
[36] Metabolic roles of endocrine fibroblast growth factors
Fernandes-Freitas, Isabel
Owen, Bryn M.
CURRENT OPINION IN PHARMACOLOGY, 2015, 25 : 30 - 35
[37] A primer on the pleiotropic endocrine fibroblast growth factor FGF19/ FGF15
Bouju, Agathe
Nusse, Roel
V. Wu, Peng
DIFFERENTIATION, 2024, 140
[38] Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)
Wu, Xinle
Ge, Hongfei
Lemon, Bryan
Vonderfecht, Steven
Baribault, Helene
Weiszmann, Jennifer
Gupte, Jamila
Gardner, Jonitha
Lindberg, Richard
Wang, Zhulun
Li, Yang
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (32) : 14158 - 14163
[39] Fibroblast growth factor 15 deficiency impairs liver regeneration in mice
Kong, Bo
Huang, Jiansheng
Zhu, Yan
Li, Guodong
Williams, Jessica
Shen, Steven
Aleksunes, Lauren M.
Richardson, Jason R.
Apte, Udayan
Rudnick, David A.
Guo, Grace L.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2014, 306 (10): : G893 - G902
[40] The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease
Chrysavgis, Lampros
Giannakodimos, Ilias
Chatzigeorgiou, Antonios
Tziomalos, Konstantinos
Papatheodoridis, George
Cholongitas, Evangelos
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (09) : 835 - 849

← 1 2 3 4 5 →